Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2000, p. 1063-1071, Vol. 20, No. 3
Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York 11724-2208
Received 14 April 1999/Returned for modification 25 May
1999/Accepted 1 November 1999
Exonic splicing enhancers (ESEs) are important cis
elements required for exon inclusion. Using an in vitro functional
selection and amplification procedure, we have identified a novel ESE
motif recognized by the human SR protein SC35 under splicing
conditions. The selected sequences are functional and specific: they
promote splicing in nuclear extract or in S100 extract complemented by SC35 but not by SF2/ASF. They can also function in a different exonic
context from the one used for the selection procedure. The selected
sequences share one or two close matches to a short and highly
degenerate octamer consensus, GRYYcSYR. A score matrix was generated
from the selected sequences according to the nucleotide frequency at
each position of their best match to the consensus motif. The SC35
score matrix, along with our previously reported SF2/ASF score matrix,
was used to search the sequences of two well-characterized splicing
substrates derived from the mouse immunoglobulin M (IgM) and human
immunodeficiency virus tat genes. Multiple SC35 high-score
motifs, but only two widely separated SF2/ASF motifs, were found in the
IgM C4 exon, which can be spliced in S100 extract complemented by SC35.
In contrast, multiple high-score motifs for both SF2/ASF and SC35 were
found in a variant of the Tat T3 exon (lacking an SC35-specific
silencer) whose splicing can be complemented by either SF2/ASF or SC35.
The motif score matrix can help locate SC35-specific enhancers in
natural exon sequences.
Accurate removal of introns from
pre-mRNA requires multiple cis elements, including the
splice sites, polypyrimidine tract, branch site, and other intronic and
exonic sequences that have positive or negative effects on splicing
(10, 31, 44); reviewed in references (1 and 2).
Positive-acting sequences, termed exonic splicing enhancers (ESEs)
(37, 39, 42), have been identified primarily in exons
associated with regulated splicing. These exons are typically adjacent
to introns with weak intronic splicing signals and require ESEs for
their inclusion. Deletion of an ESE often causes exon skipping or, in
the case of terminal exons, suppresses removal of the last intron. One
of the first characterized ESEs is located in the M2 3'-terminal exon
of the mouse immunoglobulin M (IgM) gene (39). This
73-nucleotide (nt) ESE, which is highly purine rich, is required for
inclusion of the alternatively spliced M2 exon. However, deletion of
just the purine-rich sequences within this ESE does not abolish
splicing completely. The M2 ESE also functions in a heterologous
context to enhance splicing of a Drosophila melanogaster
doublesex intron (39).
A SELEX procedure has been used to identify sequences that can function
as ESEs (36). A 20-nt sequence of the internal duplicated exon of a model pre-mRNA was replaced by 20 nt of random sequence. The
randomized pre-mRNAs were incubated under splicing conditions in
nuclear extract, and functional enhancer elements that promoted splicing were selected. A large number of sequences, both purine rich
and non-purine rich were obtained, and the two types of sequences stimulated exon inclusion to similar extents. A similar approach was
used in an in vivo system involving transfection of a troponin minigene
with random sequences in place of a natural ESE (9). Purine-rich sequences and a novel class of AC-rich ESE sequences were
identified. The AC-rich sequences are efficient splicing enhancers and
can also function in a heterologous gene context.
Considerable evidence suggests that ESEs interact specifically with a
family of RNA-binding proteins called SR proteins, which are
characterized by one or two RNA recognition motifs (RRMs) and a
C-terminal Arg-Ser-rich domain (12, 18, 27, 34, 37, 38). SR
proteins are essential splicing factors required for both constitutive
and alternative splicing (11, 17, 43). SR proteins can
determine alternative splice site selection by antagonizing the
activity of hnRNP A/B proteins. High concentrations of SR proteins
usually favor the use of proximal splice sites and exon inclusion,
whereas high concentrations of hnRNP A/B proteins tend to favor distal
splice sites and exon skipping (5, 22, 25). SR proteins also
specifically recognize ESEs, and the resulting complex may then
stimulate U2AF binding to the weak polypyrimidine tract of the upstream
3' splice site. The ESE-SR protein-U2AF interaction is thought to be
important during the early stages of spliceosome assembly (8, 16,
41, 45), although recent evidence suggests that, in at least some
cases, including the IgM M2 exon, ESEs act in part by neutralizing
exonic silencer elements (7, 15). SF2/ASF and SC35 are two
of the best characterized among the nine human SR proteins identified
to date. Both proteins have been implicated in many aspects of
constitutive and regulated splicing. Both are found in the
prespliceosomal E complex and can interact with U1-70K and U2AF by RS
domain-mediated protein-protein interactions. The RRMs of these two
proteins are responsible for their unique substrate specificities
(6, 26).
A better understanding of the functional interactions between ESEs and
SR proteins depends on knowledge of the sequence specificity of all SR
proteins. To this end, we recently performed an iterative selection
under splicing conditions to identify exon sequences that can enhance
splicing in the presence of each of three SR proteins. We identified
three novel classes of functional ESE motifs recognized specifically by
SF2/ASF, SRp40, and SRp55. The consensus motifs indicated that
individual SR proteins recognize distinct and highly degenerate
sequences (20). The three SR proteins we studied previously
are closely related, i.e., they all have two tandem RRMs. To extend
this analysis, we have now determined the sequence specificity of an
additional, extensively studied SR protein, SC35, which has a single
N-terminal RRM.
Preparation of HeLa cell extract and recombinant SR
proteins.
HeLa nuclear and S100 extracts were prepared as
described (23). Recombinant SC35 expressed in baculovirus
was generously provided by K. Lynch and T. Maniatis and by R.-M. Xu.
Selection and amplification procedure.
The amplification and
selection procedure was carried out as described (20).
Briefly, the natural ESE of the IgM pre-mRNA was replaced by 20 nt of
random sequence by overlap-extension PCR with plasmid µM Sequence analysis and construction of score matrices.
The
selected sequences of each SR protein winner pool plus a portion of the
flanking nucleotides were aligned by using Gibbs sampler
(19). The identified consensus motif was then used to generate a score matrix. The compositional bias of the initial RNA pool
was taken into account. For details of the sequence analysis, see
reference (20).
In vitro splicing.
PCR products carrying an SP6 or T7
promoter were used for in vitro transcription. 5'-capped transcripts
were incubated in 25-µl splicing reaction mixtures as previously
described (24). Each reaction mixture had 4 µl of nuclear
extract or 7 µl of S100 extract. For S100 complementation assays, 20 pmol of specific SR protein was used. Splicing reactions were carried
out at 30°C for 4 h. The RNA was then extracted, loaded on 6 or
12% polyacrylamide gels, and visualized by autoradiography
(20). DNA templates for IgM M1-M2 pre-mRNAs with a D2
variant containing an SC35 consensus match or with the 6-24 winner
sequence (29) were made by overlap-extension PCR with
primers M2-D2HXL
(GTGAAATGACTCTCAGCATggggacatactcggcccctgCTAGTAAACTTATTCTTACGT) and M2-SCH24
(GTGAAATGACTCTCAGCATtttgcggtctccggcctccCTAGTAAACTTATTCTTACGT), respectively (shared flanking sequences are in uppercase
letters). DNA templates for pre-mRNAs in an IgM C3-C4 context were made by PCR on pµC3-C4 plasmid DNA (40) with an SP6 promoter
primer and the following antisense primers: Ca
(TGGCAGCAGGTACACAGC), CaCb (gtggctgactccctcagg),
D2
(ctgcggccgagtatgtccccTGGCAGCAGGTACACAGC) D2C (caggggccgagtatgtccccTGGCAGCAGGTACACA GC)
and 6-24 (ggaggccggagaccgcaaaTGGCAGCAGGTACACAGC). RNAs
were made as described above.
Identification of ESE motifs recognized by SC35 under splicing
conditions.
To study the sequence specificity of ESE recognition
by SC35 under splicing conditions, a functional SELEX procedure
(20) was used (Fig. 1).
Functional ESEs were selected in the context of a well-characterized
mouse immunoglobulin µ heavy chain minigene transcript, comprising
the last intron flanked by the M1 and M2 exons (39). The
natural ESE in the M2 exon was replaced by 20 nt of random sequence by
overlap-extension PCR. The random RNA pool, a library of pre-mRNAs
representing 1.2 × 1010 different molecules, was
spliced in nuclear extract or in S100 extract complemented by SC35. As
previously reported, the wild-type IgM pre-mRNA spliced very
efficiently in nuclear extract, with the mature mRNA representing
greater than 90% of the RNA after a 4-h incubation (Fig. 2, lane
1). In contrast, the mutant with a
deletion of ESE (ED) did not splice at all under the same conditions (Fig. 2, lane 2), confirming that the natural ESE of the IgM pre-mRNA is essential for splicing (39). The initial RNA pool was
spliced in nuclear extract with an apparent efficiency of about 20%
(Fig. 2, lane 3), whereas no splicing was detected in the S100 extract alone (lane 4). When the S100 extract was complemented by SC35, splicing of the initial RNA pool remained undetectable by
autoradiography (lane 5). However, we assumed that a very small
fraction of the RNA pool was correctly spliced, and we excised a gel
slice corresponding to the position of spliced mRNA, using the product
in lane 3 as a marker. RNA was eluted from the gel slice and amplified
by RT-PCR. The amplified products were cloned, and 30 clones were
sequenced. The resulting sequences were analyzed by using the program
GIBBS sampler to determine a consensus sequence (19, 20). A
score matrix was generated according to the frequency of each
nucleotide at each position of the consensus motif, adjusted for the
compositional bias of the initial random pool. This score matrix was
used to identify high-score motifs within each winner sequence, taking into account the randomized sequence region and a small portion of the
flanking sequences.
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Exonic Splicing Enhancer Motif Recognized by Human
SC35 under Splicing Conditions


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
DNA
(39) as a template. The resulting PCR product was used for
in vitro transcription to generate a 32P-labeled random
pre-mRNA pool. Twenty femtomoles of the pre-mRNA pool was incubated
under in vitro splicing conditions in S100 extract plus recombinant
SC35 in a 25-µl reaction mixture. The RNA was separated by denaturing
polyacrylamide gel electrophoresis, and the spliced mRNAs were excised
and eluted from the gel in 0.5 M ammonium acetate plus 0.1% sodium
dodecyl sulfate and reamplified by reverse transcription-PCR (RT-PCR).
Reverse transcription was carried out by using Superscript II as
described by the manufacturer (Life Technologies). PCR was performed by
using high-fidelity Pfu polymerase as specified by the
manufacturer (Stratagene). The PCR product was subcloned into the
vector PCR-Blunt (Stratagene) and sequenced by using a Dye Terminator
Cycle Sequencing kit (Perkin-Elmer) and an automated ABI 377 sequencer.
Selected winner sequences were rebuilt into DNA templates for
transcription of pre-mRNAs by overlap-extension PCR, as done initially
for the random sequences (20).
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (15K):
[in a new window]
FIG. 1.
Experimental procedure for functional SELEX. The
structure of the IgM M1-M2 minigene pre-mRNA is shown. The
characterized natural ESE (73 nt) was replaced by 20 nt of randomized
sequence by overlap-extension PCR (20). A T7 promoter (black
box) was built into the PCR product. In vitro-transcribed RNA was then
incubated under splicing conditions. Any spliced mRNA molecules must
contain a functional ESE or winner sequence, designated by the white W
in a black box. The spliced mRNA molecules were purified from a
denaturing polyacrylamide gel, reamplified by RT-PCR, and cloned.
Individual clones were sequenced and analyzed by a sampling algorithm
to define a common motif, and a subset was rebuilt into minigene
templates, transcribed, and assayed for splicing in vitro.

View larger version (34K):
[in a new window]
FIG. 2.
Splicing of the initial RNA pool. Twenty femtomoles of
wild-type IgM minigene pre-mRNA (W; lane 1), pre-mRNA with a deletion
of the ESE (ED; lane 2), or a pre-mRNA pool representing 1.2 × 1010 different molecules with a randomized 20-nt segment
within exon M2 were spliced in 25-µl reaction mixtures in nuclear
extract (lane 3), S100 extract alone (lane 4), or S100 extract
complemented by 20 pmol of recombinant SC35 (lane 5). The structures of
the precursor, intermediates, and products are indicated next to the
autoradiogram. The expected size of the spliced mRNA product of the ESE
deletion mutant is indicated by an arrow.
7, t test with df = 58).
|
The SC35-selected sequences are functional and specific ESEs. We next tested whether the individual sequences selected in the presence of SC35 could function as true splicing enhancers. Five sequences with a range of scores were arbitrarily chosen from the 30 analyzed sequences and individually rebuilt into IgM M1-M2 pre-mRNAs with the same structure as those in Fig. 1 and 2, using overlap-extension PCR and in vitro transcription (20). Each pre-mRNA was then incubated under splicing conditions in nuclear extract or in S100 extract complemented by SC35 (Fig. 4). Four of the five SC35 winner sequences activated IgM pre-mRNA splicing very efficiently in nuclear extract (Fig. 4, lanes 1, 4, 7, and 10). They also promoted IgM pre-mRNA splicing in S100 extract complemented by SC35, albeit less efficiently (Fig. 4, lanes 3, 6, 9, and 12), but not in S100 extract alone (Fig. 4, lanes 2, 5, 8, and 11). One winner sequence from the SC35 winner pool, D5, enhanced splicing less efficiently in nuclear extract (Fig. 4, lane 13) and gave only trace activity in the complementation assay (Fig. 4, lane 15). In general, the splicing efficiency correlated with the motif scores shown in Fig. 3. D1 and D2 have the highest scores; D3 and D4 have intermediate scores; and D5 has the lowest score among the 30 sequences analyzed (Fig. 3). However, the correlation between splicing efficiency and motif scores is not linear, presumably reflecting sequence context effects. Also, D3 has a higher score than D4, and although they spliced with similar efficiency in nuclear extract, D4 spliced more efficiently in the complementation assay. Sixteen sequences from the random RNA pool were also analyzed for enhancer activity (20). All of them spliced in nuclear extract poorly or not at all. In most cases the pre-mRNAs showed partial degradation, suggesting that spliceosomal complexes did not assemble on these RNAs (H.-X. Liu and A. R. Krainer, unpublished data).
|
|
Comparison of SC35 ESE motifs and activity in different exonic contexts. To test whether an octamer with the highest possible SC35 ESE score has enhancer activity and to compare this consensus with a previously identified one, we analyzed the D2 winner containing the motif GGCCGCAG, a variant of D2 with two transversions that create the maximum score consensus GGCCCCUG, and one of the 19mer winners (6-24) selected by Schaal and Maniatis (29). These three sequences were first tested in the context of the IgM M2 exon (Fig. 6A). All three sequences strongly promoted splicing of exons M1 and M2 in nuclear extract (Fig. 6A, lanes 3 to 5), in contrast to the lack of detectable splicing with the parent pre-mRNA in which the natural ESE was deleted (Fig. 6A, lane 1).
|
Distribution of SC35 ESE motifs in natural genes. To determine whether the selected ESE motifs are relevant to splicing of natural pre-mRNA substrates, we conducted a search of SC35 high-score motifs in natural genes. Only scores higher than the lowest score of the SC35 winner pool are shown (Fig. 7, green vertical bars). For comparison, we also show the high-score SF2/ASF motifs in the same genes (Fig. 7, blue vertical bars) (20). The first natural sequence we examined was the M2 exon of the IgM gene. The search result indicated that there are many SC35 ESE motifs within the segment comprising the previously characterized natural ESE (Fig. 7A, magenta horizontal bar). The distribution of high-score SC35 motifs differs from that of SF2/ASF motifs. SF2/ASF-specific motifs are present at a higher density within the natural ESE than in the flanking regions. In contrast, high-score SC35 motifs have a relatively even distribution across the M2 exon. Both SR proteins can promote splicing of this pre-mRNA in S100 extract (Liu and Krainer, unpublished). The presence of ESE motifs in regions lacking enhancer activity shows that although the motifs may be necessary, they are not sufficient for ESE function (see Discussion).
|
10).
| |
DISCUSSION |
|---|
|
|
|---|
We have identified a novel ESE motif recognized by the human SR protein SC35. Several lines of evidence point to the biological relevance of the selected ESE motifs. First, they are functional ESEs. All of the SELEX winners we have tested promote splicing in nuclear extract and in S100 extract plus the cognate SR protein. In nuclear extract, the SELEX winners function as potent ESEs. Second, the SC35 motifs are present within exon segments containing natural ESEs and are more frequently found in exons than in introns, suggesting that they may contribute to exon definition by the spliceosome. Third, the SC35 motifs are specific, i.e., they are not recognized by all SR proteins. The SC35-selected ESEs were recognized by SC35, SRp40, or SRp55, but not by SF2/ASF under splicing conditions. In addition, the distribution of high-score motifs of SF2/ASF and SC35 in the IgM C4 and Tat T3 exons correlated with the observed SR protein specificity of the corresponding substrates (26). This result also suggests that the score matrices we have generated have some predictive value. We have previously analyzed the predictive value of the SR-specific score matrices derived for other SR proteins (20). Statistically, high-score motifs of SR proteins are present at a higher density in natural ESEs than in the flanking regions. Experimentally, SR proteins specifically recognize their cognate ESE motifs when these are placed in the context of the IgM M2 exon, replacing the natural ESE. The present study confirms and extends our previous work to two natural ESEs in IgM and human immunodeficiency virus Tat exons. In addition, we have now shown that SC35 winner sequences and a maximum-score SC35 motif can promote splicing in different exonic contexts.
The specific interaction between SR proteins and ESEs has also been described in other systems. During assembly of enhancer complexes in vitro (Enh complex, which resembles the E complex), the enhancer sequences determine the specific pattern of SR proteins that can be UV cross-linked to the RNA (32). Female-specific alternative splicing of the Drosophila doublesex pre-mRNA requires six 13-nt repeat elements and a purine-rich element. UV cross-linking analysis showed that SR proteins, along with Tra and Tra-2, assemble on the ESEs in a stepwise and sequence-specific manner (21). The fact that SR proteins are expressed in a tissue-specific manner (14, 43), together with the specific recognition of ESEs by individual SR proteins may contribute quantitatively to the regulation of gene expression.
The SC35 SELEX winners have the consensus GRYYcSYR, which is a highly degenerate sequence. Even though SC35 has a single RRM, a SELEX protocol based on RNA binding yielded two different nonamer consensus sequences, AGSAGAGTA and GTTCGAGTA, which share the last five nucleotides (35). These two motifs differ significantly from the more degenerate consensus identified by functional SELEX. Although the second motif has a partial fit to the above consensus, neither motif has a good score, consistent with the observation that the high-affinity binding sequences fail to enhance splicing of RNA substrates in nuclear extract or in S100 extract plus SC35, even when present in several copies (35). Therefore, it appears that high-affinity SC35-binding sites are not optimal for function. Perhaps RNA-binding selection does not achieve an interaction geometry compatible with SC35 enhancement function, or it is essential to coselect sequences that in addition to binding SC35 can also accommodate putative coactivators or fail to bind silencing factors.
Nevertheless, our data argue that SC35 has limited but defined sequence specificity in recognizing functional sequences. Despite the fact that this protein has a single RRM, the functional recognition motif is degenerate, as was the case for the two-RRM SR proteins SF2/ASF, SRp40, and SRp55 (20). Therefore, the degeneracy of the ESE motifs recognized by those proteins is probably not attributable to the recognition of distinct motifs by each of their RRMs. The sequence degeneracy of the ESEs is consistent with the fact that they must coexist with a very wide variety of unrelated open reading frames and must be recognized by a discrete set of SR proteins (20, 28, 29).
Schaal and Maniatis recently used a similar functional SELEX approach
to select ESEs that could function in the context of the
Drosophila doublesex pre-mRNA in HeLa nuclear extract
(29). The selected 18-nt winner sequences were then
individually analyzed by S100 complementation assays to define their SR
protein specificity. Two round 6 winner sequences were the most active
in the presence of SC35. By comparing these two sequences to each other
and to an SC35-dependent ESE present in human
-globin exon 2, the
authors proposed the SC35 heptamer consensus UGCNGYY, which
is also a highly degenerate sequence. Although this heptamer motif is
substantially different from our consensus octamer motif, some versions
of the degenerate heptamer consensus have high scores, as defined in the present study. We therefore searched the two published winner sequences (29) by using our SC35 score matrix. Both
sequences had multiple high-score motifs, some of which were
nonoverlapping, consistent with the fact that they had undergone six
rounds of selection for splicing. In the case of the 6-24 sequence, the highest score (3.13) corresponded to the octamer GGUCUCCG,
which has a 4-nt overlap with the UGCGGUC sequence
that fits the heptamer consensus. In the case of the 6-38 sequence, the
second highest score (1.56) corresponds to the octamer UGCCGCC,
of which the first 7 nt fit the heptamer consensus; the highest
score (2.44) was for the nonoverlapping octamer GGACCGGA.
Similarly, within the 18-nt
-globin fragment in which Schaal
and Maniatis characterized an SC35-dependent ESE that comprises the
heptamer UGCUGUU (28), the highest score (1.36)
corresponds to the octamer UGAUGCUG, which includes the
first 5 nt of the heptamer.
We conclude that despite the very different pre-mRNA contexts, types of
extract used for the selection, and number of selection rounds, the
SC35 ESEs identified by the two approaches are remarkably consistent.
We believe, however, that our octamer motif has greater predictive
value because it was derived from a much larger number of winner
sequences. Also, the use of a nucleotide frequency matrix derived from
30 sequences allows identification of putative SC35 ESEs that do not
precisely match the consensus at every position. Thus, our SC35 score
matrix finds high-score motifs in both of the winner sequences and the
-globin segment characterized by Schaal and Maniatis (28,
29), whereas of our 30 SC35 winner sequences (Fig. 3), only no.
14 has a precise match to the heptamer consensus they defined.
The IgM M2 exon has a higher density of SF2/ASF and SRp40 high-score motifs within the natural ESE segment than in the flanking sequences. In contrast, the SRp55 high-score motifs do not correlate with the location of the ESE (20). In the case of SC35, the high-score motifs also have a relatively even distribution across the exon. The different motif distributions may reflect different mechanisms of SR protein-ESE recognition. Although for some pre-mRNAs any SR protein can complement splicing in the S100 extract (30, 43), each SR protein may function by slightly different mechanisms. Some SR proteins may require multiple binding sites to function, and the optimal distance from the 3' splice site to the SR protein-binding site may also be protein specific. The fact that ESE motifs are not found exclusively in natural exonic segments required for ESE activity indicates that the motifs are not sufficient for ESE function. It appears that sequence context, structure, or position effects are also very important.
Examples of sequence context effects that can influence ESE activity are provided by exonic splicing silencers. These inhibitory elements probably coexist with splicing enhancers in many exons, and they may also be SR protein dependent and function in a cell-type specific manner. For example, an SC35-dependent silencer sequence has been mapped in the tat gene T3 exon (26). This silencer element includes within it an SC35-specific ESE motif (Fig. 7C). We speculate that binding of SC35 to this region prevents the function of other splicing factors, although it is presently unclear how this element acts at a distance and suppresses the effect of SC35-dependent ESEs but not of SF2/ASF-dependent ESEs. Recently, the 3' portion of the IgM M2 exon was also shown to comprise a silencer element that binds U2 snRNP and antagonizes the upstream ESE (15). The silencer element, so far mapped to a fragment between nt 94 and 167 (Fig. 7A) in the M2 exon, overlaps with several SC35 high-score motifs and with one SF2/ASF high-score motif.
The similar arrangement of adjacent ESE and exonic splicing silencer elements seen in the IgM M2 and Tat T3 exons may turn out to be a common feature of many vertebrate cellular and viral exons. To improve the predictive value of the SR protein-specific ESE motifs, it will be necessary to gain a better understanding of the influence of sequence context and position, as well as of the mechanistic basis for the function of splicing enhancers and silencers.
| |
ACKNOWLEDGMENTS |
|---|
We thank Y. Shimura for the gift of IgM plasmids, K. Lynch, T. Maniatis, R.-M. Xu, and A. Mayeda for recombinant SR proteins, J. Yin for DNA sequencing, A. Mayeda and members of our laboratory for valuable ideas, and M. Hastings for helpful comments on the manuscript.
This work was supported by NIH grants to A.R.K. (GM42699) and M.Q.Z. (HG01696), by an Advanced Fellowship from The Wellcome Trust to S.L.C. (045401), by a fellowship from the Human Frontiers Science Program to L.C. (LT0066/1997-M), and by a fellowship from the U.S. Army Medical Research and Matériel Command under DAMD 17-96-1-6172 to H.-X.L.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Cold Spring Harbor Laboratory, 1 Bungtown Rd., P.O. Box 100, Cold Spring Harbor, NY 11724-2208. Phone: (516) 367-8417. Fax: (516) 367-8453. E-mail: krainer{at}cshl.org.
Present address: Phylos Inc., Lexington, MA 02421.
Present address: Department of Endocrinology, St. Bartholomew's
and the Royal London School of Medicine and Dentistry, London EC1A 7BE,
United Kingdom.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Berget, S. M.
1995.
Exon recognition in vertebrate splicing.
J. Biol. Chem.
270:2411-2414 |
| 2. | Black, D. L. 1995. Finding splice sites within a wilderness of RNA. RNA 1:763-771[Medline]. |
| 3. | Burge, C. B., T. Tuschl, and P. A. Sharp. 1999. Splicing of precursors to mRNAs by the spliceosomes, p. 525-559. In R. F. Gesteland, T. R. Cech, and J. F. Atkins (ed.), The RNA world, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 4. | Burset, M., and R. Guigo. 1996. Evaluation of gene structure prediction programs. Genomics 34:353-367[CrossRef][Medline]. |
| 5. |
Cáceres, J. F.,
S. Stamm,
D. M. Helfman, and A. R. Krainer.
1994.
Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.
Science
265:1706-1709 |
| 6. |
Chandler, S. D.,
A. Mayeda,
J. M. Yeakley,
A. R. Krainer, and X.-D. Fu.
1997.
RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins.
Proc. Natl. Acad. Sci. USA
94:3596-3601 |
| 7. |
Chew, S. L.,
H.-L. Liu,
A. Mayeda, and A. R. Krainer.
1999.
Evidence for the function of an exonic splicing enhancer after the first catalytic step of pre-mRNA splicing.
Proc. Natl. Acad. Sci. USA
96:10655-10660 |
| 8. | Chiara, M. D., and R. Reed. 1995. A two-step mechanism for 5' and 3' splice-site pairing. Nature 375:510-513[CrossRef][Medline]. |
| 9. | Coulter, L. R., M. A. Landree, and T. A. Cooper. 1997. Identification of a new class of exonic splicing enhancers by in vivo selection. Mol. Cell. Biol. 17:2143-2150[Abstract]. (Erratum, 17:3468.) |
| 10. |
Freyer, G. A.,
J. P. O'Brien, and J. Hurwitz.
1989.
Alterations in the polypyrimidine sequence affect the in vitro splicing reactions catalyzed by HeLa cell-free preparations.
J. Biol. Chem.
264:14631-14637 |
| 11. | Ge, H., P. Zuo, and J. L. Manley. 1991. Primary structure of the human splicing factor ASF reveals similarities with Drosophila regulators. Cell 66:373-382[CrossRef][Medline]. |
| 12. | Gontarek, R. R., and D. Derse. 1996. Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing. Mol. Cell. Biol. 16:2325-2331[Abstract]. |
| 13. |
Gorodkin, J.,
L. J. Heyer,
S. Brunak, and G. D. Stormo.
1997.
Displaying the information contents of structural RNA alignments: the structure logos.
Comput. Appl. Biosci.
13:583-586 |
| 14. | Hanamura, A., J. F. Cáceres, A. Mayeda, B. R. Franza, Jr., and A. R. Krainer. 1998. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430-444[Abstract]. |
| 15. |
Kan, J. L., and M. R. Green.
1999.
Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor.
Genes Dev.
13:462-471 |
| 16. | Kohtz, J. D., S. F. Jamison, C. L. Will, P. Zuo, R. Lührmann, M. A. Garcia-Blanco, and J. L. Manley. 1994. Protein-protein interactions and 5'-splice-site recognition in mammalian mRNA precursors. Nature 368:119-124[CrossRef][Medline]. |
| 17. | Krainer, A. R., A. Mayeda, D. Kozak, and G. Binns. 1991. Functional expression of cloned human splicing factor SF2: homology to RNA-binding proteins, U1 70K, and Drosophila splicing regulators. Cell 66:383-394[CrossRef][Medline]. |
| 18. |
Lavigueur, A.,
H. La Branche,
A. R. Kornblihtt, and B. Chabot.
1993.
A splicing enhancer in the human fibronectin alternate ED1 exon interacts with SR proteins and stimulates U2 snRNP binding.
Genes Dev.
7:2405-2417 |
| 19. |
Lawrence, C. E.,
S. F. Altschul,
M. S. Boguski,
J. S. Liu,
A. F. Neuwald, and J. C. Wootton.
1993.
Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment.
Science
262:208-214 |
| 20. |
Liu, H.-X.,
M. Zhang, and A. R. Krainer.
1998.
Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins.
Genes Dev.
12:1998-2012 |
| 21. |
Lynch, K. W., and T. Maniatis.
1996.
Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer.
Genes Dev.
10:2089-2101 |
| 22. |
Mayeda, A.,
D. M. Helfman, and A. R. Krainer.
1993.
Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF.
Mol. Cell. Biol.
13:2993-3001 |
| 23. | Mayeda, A., and A. R. Krainer. 1999. Preparation of Hela cell nuclear and cytosolic S100 extracts for in vitro splicing. Methods Mol. Biol. 118:309-314[Medline]. |
| 24. | Mayeda, A., and A. R. Krainer. 1999. Mammalian in vitro splicing assays. Methods Mol. Biol. 118:315-322[Medline]. |
| 25. | Mayeda, A., and A. R. Krainer. 1992. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 68:365-375[CrossRef][Medline]. |
| 26. |
Mayeda, A.,
G. R. Screaton,
S. D. Chandler,
X.-D. Fu, and A. R. Krainer.
1999.
Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements.
Mol. Cell. Biol.
19:1853-1863 |
| 27. | Ramchatesingh, J., A. M. Zahler, K. M. Neugebauer, M. B. Roth, and T. A. Cooper. 1995. A subset of SR proteins activates splicing of the cardiac troponin T alternative exon by direct interactions with an exonic enhancer. Mol. Cell. Biol. 15:4898-4907[Abstract]. |
| 28. |
Schaal, T. D., and T. Maniatis.
1999.
Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA.
Mol. Cell. Biol.
19:261-273 |
| 29. |
Schaal, T. D., and T. Maniatis.
1999.
Selection and characterization of pre-mRNA splicing enhancers: identification of novel SR protein-specific enhancer sequences.
Mol. Cell. Biol.
19:1705-1719 |
| 30. | Screaton, G. R., J. F. Cáceres, A. Mayeda, M. V. Bell, M. Plebanski, D. G. Jackson, J. I. Bell, and A. R. Krainer. 1995. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. EMBO J. 14:4336-4349[Medline]. |
| 31. |
Seif, I.,
G. Khoury, and R. Dhar.
1979.
BKV splice sequences based on analysis of preferred donor and acceptor sites.
Nucleic Acids Res.
6:3387-3398 |
| 32. |
Staknis, D., and R. Reed.
1994.
SR proteins promote the first specific recognition of pre-mRNA and are present together with the U1 small nuclear ribonucleoprotein particle in a general splicing enhancer complex.
Mol. Cell. Biol.
14:7670-7682 |
| 33. | Stormo, G. D. 1990. Consensus patterns in DNA. Methods Enzymol. 183:211-237[Medline]. |
| 34. |
Sun, Q.,
A. Mayeda,
R. K. Hampson,
A. R. Krainer, and F. M. Rottman.
1993.
General splicing factor SF2/ASF promotes alternative splicing by binding to an exonic splicing enhancer.
Genes Dev.
7:2598-2608 |
| 35. | Tacke, R., and J. L. Manley. 1995. The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J. 14:3540-3551[Medline]. |
| 36. | Tian, H., and R. Kole. 1995. Selection of novel exon recognition elements from a pool of random sequences. Mol. Cell. Biol. 15:6291-6298[Abstract]. |
| 37. | Tian, M., and T. Maniatis. 1993. A splicing enhancer complex controls alternative splicing of doublesex pre-mRNA. Cell 74:105-114[CrossRef][Medline]. |
| 38. |
Tian, M., and T. Maniatis.
1994.
A splicing enhancer exhibits both constitutive and regulated activities.
Genes Dev.
8:1703-1712 |
| 39. |
Watakabe, A.,
K. Tanaka, and Y. Shimura.
1993.
The role of exon sequences in splice site selection.
Genes Dev.
7:407-418 |
| 40. |
Watakabe, A.,
K. Inoue,
H. Sakamoto, and Y. Shimura.
1989.
A secondary structure at the 3' splice site affects the in vitro splicing reaction of mouse immunoglobulin µ chain pre-mRNAs.
Nucleic Acids Res.
17:8159-8169 |
| 41. | Wu, J. Y., and T. Maniatis. 1993. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 75:1061-1070[CrossRef][Medline]. |
| 42. |
Xu, R.,
J. Teng, and T. A. Cooper.
1993.
The cardiac troponin T alternative exon contains a novel purine-rich positive splicing element.
Mol. Cell. Biol.
13:3660-3674 |
| 43. |
Zahler, A. M.,
K. M. Neugebauer,
W. S. Lane, and M. B. Roth.
1993.
Distinct functions of SR proteins in alternative pre-mRNA splicing.
Science
260:219-222 |
| 44. |
Zhuang, Y. A.,
A. M. Goldstein, and A. M. Weiner.
1989.
UACUAAC is the preferred branch site for mammalian mRNA splicing.
Proc. Natl. Acad. Sci. USA
86:2752-2756 |
| 45. |
Zuo, P., and T. Maniatis.
1996.
The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing.
Genes Dev.
10:1356-1368 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»